MaaT013

MaaT Pharma completed Phase 3 trial enrolment for MaaT013, treating steroid-refractory acute graft-versus-host disease, with initial results expected from Jan 2025. Shares rose 1.1% on Paris Bourse.

MaaT Pharma completed recruitment for its Phase 3 trial evaluating MaaT013 in steroid and ruxolitinib refractory GI-aGvHD, enrolling 66 evaluable patients. Topline results expected in January 2025.

MaaT Pharma completes recruitment for its ARES Phase 3 trial evaluating MaaT013 for acute Graft-versus-Host Disease, with topline results expected in January 2025. The trial received a positive DSMB review in Q4 2023, highlighting high efficacy and low toxicity. Registration submission is planned for 2025 in Europe.

MaaT Pharma completed Phase 3 ARES trial enrollment for MaaT013 in treating steroid and ruxolitinib refractory acute Graft-versus-Host Disease (aGvHD), with topline results expected in January 2025. The trial received positive DSMB review in Q4 2023, indicating high efficacy and low toxicity. Registration process for MaaT013 is set to begin in 2025 in Europe.

MaaT Pharma announced full recruitment for its Phase 3 trial of MaaT013, targeting steroid and ruxolitinib refractory aGvHD, with topline results expected by January 2025. CEO Hervé Affagard highlighted the trial's significance for cancer patients and MaaT013's potential as a novel microbiome-driven therapy. The ARES study enrolled 66 patients, showing high efficacy and low toxicity in interim analyses.

Graft versus Host Disease Market to grow at 9.9% CAGR (2020-2034), driven by branded therapies, strong pipeline, and increased awareness. Market size in the US was $1 billion in 2023, expected to grow at 7.4% CAGR (2024-2034). Emerging therapies like Axatilimab and CSL964 to transform market. Key companies include Equillium, Biocon, Takeda, and CSL Behring.

MaaT Pharma announces a €18 million offering to fund Microbiome Ecosystem Therapies development, including Phase 3 trials for MaaT013 and MaaT033. The offering includes new shares at €8 each, with €14.3m committed by historical shareholders. The company aims to extend its cash runway into early 2025.

The CEO of MaaT Pharma, with a background in IT and biotech, co-founded the company focusing on microbiome therapies for oncology. MaaT Pharma is advancing in clinical trials for its lead product, MaaT013, targeting GI-aGvHD, and MaaT033 for HSCT recipients, aiming to improve cancer treatment outcomes through microbiome modulation.

MaaT Pharma secured an additional €7.35 million in Series B financing, totaling €25.35 million, to advance its microbiome restoration biotherapeutics platform. The funding supports the development of next-generation microbiome ecosystem therapeutics, including MaaT013 and MaaT033 for GvHD and cancer treatment, and expands the pipeline towards solid tumors.